Why Is Monte Rosa Stock Trading Higher Today?

Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) shared interim data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC).The Phase 1/2 study evaluated 0.5 mg and 0.75 mg of MRT-2359 administered orally on a 21-days-on, 7-day-off drug schedule in combination with Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc.’s (OTC:ALPMF) (OTC:ALPMY) Xtandi (enzalutamide).The study population, as ...